Synergistic antibacterial effects of postbiotics combined with linezolid and amikacin against nosocomial pathogens
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1616501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Elif Yaprak Çolak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Medical Faculty, Hatay Mustafa Kemal University, Antakya-Hatay, Türkiye. Hauptthemen laut MEDLINE: Linezolid, Amikacin, Anti-Bacterial Agents, Drug Synergism. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim The global rise in antimicrobial resistance (AMR) has rendered many conventional antibiotics less effective, particularly against nosocomial pathogens such as Staphylococcus aureus , Escherichia coli , Pseudomonas aeruginosa , and Proteus mirabilis . This study investigated the antimicrobial and synergistic effects of postbiotics derived from Lacticaseibacillus casei , Lactobacillus bulgaricus , Enterococcus faecium , and Streptococcus thermophilus , administered alone or in combination with either linezolid (for S. aureus ) or amikacin (for Gram-negative strains). Materials and methods Postbiotics were obtained through anaerobic fermentation, followed by centrifugation and filtration. Cytotoxicity was assessed via MTT assays on Vero cell lines. Infection models involving pathogen-specific adhesion and invasion assays were used, with CFU/mL quantification and statistical evaluation by one-way ANOVA and Tukey’s post hoc test.
Results
The postbiotics exhibited potent antimicrobial activity across all tested pathogens. Combined with linezolid, the dual and triple postbiotic formulations significantly enhanced antibacterial effects against S. aureus from the early hours of incubation. Similarly, combinations with amikacin produced potent synergistic effects against E. coli , P. aeruginosa , and P. mirabilis , particularly in triple combinations involving L. casei and L. bulgaricus . Postbiotics sometimes outperformed antibiotics, such as ST+LC postbiotics against P. mirabilis . These findings suggest that postbiotics can enhance antibiotic efficacy-possibly by modulating membrane permeability, disrupting biofilms, or altering bacterial communication systems. Their low cytotoxicity and pathogen-specific responses indicate that postbiotics are safe and may be tailored for targeted use.
Conclusions
In conclusion, postbiotic-antibiotic combinations, especially with linezolid and amikacin, present promising low-toxicity, synergistic therapeutic strategies. These results lay a strong foundation for advancing microbiome-based adjunct therapies to combat AMR in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology, Medical Faculty, Hatay Mustafa Kemal University, Antakya-Hatay, Türkiye.
Zitieren
APA
Yaprak Çolak, E., & Duran, N. (2025). Synergistic antibacterial effects of postbiotics combined with linezolid and amikacin against nosocomial pathogens. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1616501
Vancouver
Yaprak Çolak E, Duran N. Synergistic antibacterial effects of postbiotics combined with linezolid and amikacin against nosocomial pathogens. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1616501
BibTeX
@article{Yaprakolak2025,
author = {Yaprak Çolak, Elif and Duran, Nizami},
title = {Synergistic antibacterial effects of postbiotics combined with linezolid and amikacin against nosocomial pathogens},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1616501}
}
EUVIMED